Sample Size Calculation for Controlling False Discovery Proportion

by Shulian Shang, Qianhe Zhou, Mengling Liu, Yongzhao Shao
Published 2012-01-01

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multip...

by Douglas L. Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L. Naylor
Published 2018-08-01

Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population.

by Paru Patrawalla, Angeliki Kazeros, Linda Rogers, Yongzhao Shao, Mengling Liu, Maria-Elena Fernandez-Beros, Shulian Shang, Joan Reibman
Published 2012-01-01

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN

by Scott D. Newsome, Thomas F. Scott, Douglas L. Arnold, Gereon Nelles, Serena Hung, Yue Cui, Shulian Shang, Maria L. Naylor, Marcelo Kremenchutzky
Published 2018-08-01

Correction: The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma

by Chanh Huynh, Laura Poliseno, Miguel F. Segura, Ratna Medicherla, Adele Haimovic, Silvia Menendez, Shulian Shang, Anna Pavlick, Yongzhao Shao, Farbod Darvishian, John F. Boylan, Iman Osman, Eva Hernando
Published 2011-01-01

The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

by Chanh Huynh, Laura Poliseno, Miguel F Segura, Ratna Medicherla, Adele Haimovic, Silvia Menendez, Shulian Shang, Anna Pavlick, Yongzhao Shao, Farbod Darvishian, John F Boylan, Iman Osman, Eva Hernando
Published 2011-01-01

Correction: The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma.

by Chanh Huynh, Laura Poliseno, Miguel F. Segura, Ratna Medicherla, Adele Haimovic, Silvia Menendez, Shulian Shang, Anna Pavlick, Yongzhao Shao, Farbod Darvishian, John F. Boylan, Iman Osman, Eva Hernando
Published 2011-01-01